Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib.
Clin Case Rep
; 9(4): 2228-2235, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1122024
ABSTRACT
An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Observational study
/
Prognostic study
Language:
English
Journal:
Clin Case Rep
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS